*4.4.2 Patients in the therapy: dropped out patients and patients who finished the therapy*

Eleven out of 63 patients (17%) dropped out before the end of the treatment. Four patients could not visit sessions due to time limitations, 7 patients dropped out without any explanation, and 52 patients finished the therapy. The mean duration of the therapeutic course for these patients was 13.5 sessions of PDP. However, in the MPT group, the mean number of sessions was 11.5, and in the PT + PPT group, this number was significantly higher—16.7 sessions (p = 0.0005).

**Scale**

**61**

 **Total (***<sup>n</sup>* **=**

**Primary therapeutic**

**WLC group at screening**

**WLC group right before the**

**MPT group**

**PT + PPT group (***<sup>n</sup>*

**PD group**

**GAD group**

> **(***<sup>n</sup>* **= 29)**

> **(***<sup>n</sup>* **= 23)**

> **(***<sup>n</sup>* **= 32)**

**= 20)**

**therapy (***<sup>n</sup>* **= 25)**

**point (***<sup>n</sup>* **= 25)**

**group (***<sup>n</sup>* **= 27)**

**52)**

*M* SCL-90 DEP 1.66 0.82

SCL-90 ANX 1.85 0.93 SCL-90 GSI 1.29 0.62

STAI-S

STAI-T

BDI

ShARS

FFMQ-SF

MAAS

*SCL-90 DEP, ANX,*  *anxiety; BDI—Beck Depression Inventory;* 

*Awareness Scale; MPT group*

*1*

p *< 0.01 (comparing to MPT group).*

*2*

p *< 0.03 (comparing to PD group).*

*3*

p *< 0.007 (comparing to PD group).*

**Table 3.**

*Means and standard deviations at screening point and right before the therapy.*

*GSI—depression,*

 *anxiety, and global severity index of symptom checklist 90;* 

*—monopsychotherapy*

 *group; PT + PPT group*

*ShARS—Sheehan*

 *Clinical Anxiety Rating Scale;* 

*—psychotherapy*

 *+* 

 3.90 0.72

 3.97

 0.76

 3.87

 0.70

 71.54 9.28

 72.60

 8.62

 71.68

 8.95

 70.40

3.82 *STAI-S—Spielberger*

*FFMQ-SF—Five-Factor*

*psychopharmacotherapy*

 *group with later* 

 *Mindfulness*

*Questionnaire,*

 *short version, total score;* 

*psychopharmacotherapy*

 *withdrawal.*

 *Anxiety Inventory, state anxiety;* 

0.68

 3.85 0.75

 3.97

 0.67 *STAI-T—Spielberger*

 *Anxiety Inventory, trait*

*MAAS—Mindfulness*

 *Attention*

 3.97 0.82 3.79 0.55

 48.77 25.47

 49.11

 21.75

 51.76

 22.10

 48.40

 29.43

9.99

 71.70 7.34

 71.28

 11.95

 72.46 9.02 70.28 9.68

 45.38 24.95

 54.20

 25.99

 56.67 25.03 38.003 22.37

 19.54 10.24

 19.96

 10.74

 19.80

 10.20

 19.08

 55.08 9.79

 54.63

 9.86

 53.72

 6.71

 55.56

 37.35 11.11

 38.59

 10.25

 36.16

 11.12

 36.00

 12.04

9.90

9.87

 18.44 8.92

 21.30

 12.09

 19.93 10.89 19.00 9.49

 52.69 8.10

 58.90

 11.19

 55.53 10.12 54.45 9.52

 34.25 6.66

 42.301

14.74

 36.80 10.83 38.09 11.71

*The Integrative Theory of Hypnosis in the Light of Clinical Hypnotherapy*

**SD**

*M*

 1.58

 1.75

 1.23

 0.66

 1.33

 0.58

1.35

0.58

 1.21 0.41

 1.42

 0.86

 1.40 0.62 1.14 0.61

 0.87

 1.75

 0.89

1.96

1.00

 1.76 0.80

 2.01

 1.11

 2.09 0.81 1.542 1.00

 0.75

 1.59

 0.81

1.74

0.90

 1.56 0.64

 1.81

 1.06

 1.68 0.77 1.62 0.91

**SD**

*М*

**SD**

*M*

**SD**

*M*

**SD**

*M*

**SD**

*M*

**SD**

*M*

**SD**

*DOI: http://dx.doi.org/10.5772/intechopen.92761*


*The Integrative Theory of Hypnosis in the Light of Clinical Hypnotherapy DOI: http://dx.doi.org/10.5772/intechopen.92761*

> **Table 3.**

p *< 0.03 (comparing to PD group).*

*3*

p *< 0.007 (comparing to PD group).*  *Means and standard deviations at screening point and right before the therapy.*

psychopharmacological medications at the beginning of the therapy). The basic clinical, demographic, and clinical-psychometric criteria of the main and control groups were compared using the Mann–Whitney test and χ<sup>2</sup> test for independent samples. The two groups did not show significant differences in all the parameters, but STAI-S score (which was significantly different in the groups of MPT and PT + PPT (p = 0.01)) and SCL-90 ANX (p = 0.03) and ShARS (p = 0.007) scores were significantly different in the PD and GAD groups (**Tables 1** and **2**). That fact

**Total (***n* **= 52)**

Vocational school 4 7.7 4 14.8 Secondary school 1 1.9 1 3.7

**Gender (female)** 35 67.3 20 74.1 15 60.0 **Age (***M***, SD)** 31.6 10.4 30.9 9 32.5 12.1

High 41 78.8 20 74.1 21 84.0 Student 6 11.5 2 7.4 4 16.0

Married/partner 23 44.2 12 44.4 11 44.0 Single 27 51.9 15 55.6 12 48.0 Divorced 2 3.8 2 8.0

PD 29 55.8 16 59.3 13 52.0 GAD 23 44.2 11 40.7 12 48.0 **Months science onset (***M***, SD)** 54.5 77.4 51.5 53.7 58.4 100.8 **PPT** 20 38.5 12 44.4 8 32.0 *Primary therapeutic group—group that began therapy right after the screening; WLC group—waiting list control*

**Primary therapeutic group (***n* **= 27)**

*n* **%** *n* **%** *n* **%**

**WLC group (***n* **= 25)**

The duration of the illness till the moment of the beginning of the treatment was also significantly different in the groups of MPT and PT + PPT (18.1 months and 112.8 months, accordingly; p < 0.0001). The mean duration of psychopharmacotherapy before the treatment in the group PT + PPT was 37.6 months. In all these cases (except 2) during this period the patients received more than two different psychopharmacological courses. These data allow us to call the PT + PPT group a

*4.4.2 Patients in the therapy: dropped out patients and patients who finished the therapy*

Eleven out of 63 patients (17%) dropped out before the end of the treatment. Four patients could not visit sessions due to time limitations, 7 patients dropped out without any explanation, and 52 patients finished the therapy. The mean duration of the therapeutic course for these patients was 13.5 sessions of PDP. However, in the MPT group, the mean number of sessions was 11.5, and in the PT + PPT group,

this number was significantly higher—16.7 sessions (p = 0.0005).

witnesses a general success of the randomization.

*group; PPT—number of subjects with psychopharmacotherapy.*

therapy-resistant group.

**60**

**Education**

*Hypnotherapy and Hypnosis*

**Marital status**

**Diagnosis**

**Table 2.**

*Patient characteristics.*
